JPMorgan Chase & Co. Has $2.17 Million Holdings in Centessa Pharmaceuticals plc (NASDAQ:CNTA)

JPMorgan Chase & Co. lifted its stake in shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) by 1,969.2% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 135,903 shares of the company’s stock after buying an additional 129,335 shares during the period. JPMorgan Chase & Co. owned about 0.10% of Centessa Pharmaceuticals worth $2,173,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. American Century Companies Inc. increased its holdings in Centessa Pharmaceuticals by 1.3% in the second quarter. American Century Companies Inc. now owns 935,151 shares of the company’s stock valued at $8,444,000 after purchasing an additional 12,031 shares during the period. XTX Topco Ltd acquired a new stake in Centessa Pharmaceuticals in the second quarter valued at $148,000. Farallon Capital Management LLC increased its holdings in Centessa Pharmaceuticals by 438.0% in the second quarter. Farallon Capital Management LLC now owns 1,996,000 shares of the company’s stock valued at $18,024,000 after purchasing an additional 1,625,000 shares during the period. First Light Asset Management LLC increased its holdings in Centessa Pharmaceuticals by 59.2% in the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock valued at $43,168,000 after purchasing an additional 1,778,515 shares during the period. Finally, Sandia Investment Management LP acquired a new stake in Centessa Pharmaceuticals in the second quarter valued at $90,000. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Insider Transactions at Centessa Pharmaceuticals

In other news, insider Gregory M. Weinhoff sold 11,742 shares of the stock in a transaction dated Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the transaction, the insider now owns 183,266 shares of the company’s stock, valued at $2,818,631.08. This represents a 6.02 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CTO Tia L. Bush sold 17,813 shares of the firm’s stock in a transaction dated Tuesday, December 17th. The shares were sold at an average price of $18.00, for a total transaction of $320,634.00. Following the completion of the transaction, the chief technology officer now directly owns 147,615 shares in the company, valued at approximately $2,657,070. The trade was a 10.77 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 349,226 shares of company stock valued at $6,036,765 in the last 90 days. 11.59% of the stock is currently owned by corporate insiders.

Wall Street Analysts Forecast Growth

CNTA has been the subject of a number of recent research reports. Guggenheim increased their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the company a “buy” rating in a report on Friday, November 15th. TD Cowen began coverage on Centessa Pharmaceuticals in a report on Tuesday, January 7th. They issued a “buy” rating for the company. Seven equities research analysts have rated the stock with a buy rating, According to MarketBeat, Centessa Pharmaceuticals has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA opened at $16.46 on Wednesday. The company has a current ratio of 21.52, a quick ratio of 21.52 and a debt-to-equity ratio of 0.15. The stock has a market capitalization of $2.17 billion, a P/E ratio of -10.76 and a beta of 1.53. The firm’s fifty day simple moving average is $16.83 and its two-hundred day simple moving average is $14.77. Centessa Pharmaceuticals plc has a 12 month low of $7.38 and a 12 month high of $18.97.

Centessa Pharmaceuticals (NASDAQ:CNTA) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. As a group, analysts predict that Centessa Pharmaceuticals plc will post -1.6 EPS for the current year.

Centessa Pharmaceuticals Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.